Circulating Exosomal microRNAs as Biomarkers of Colon Cancer

Purpose Exosomal microRNAs (miRNAs) have been attracting major interest as potential diagnostic biomarkers of cancer. The aim of this study was to characterize the miRNA profiles of serum exosomes and to identify those that are altered in colorectal cancer (CRC). To evaluate their use as diagnostic biomarkers, the relationship between specific exosomal miRNA levels and pathological changes of patients, including disease stage and tumor resection, was examined. Experimental Design Microarray analyses of miRNAs in exosome-enriched fractions of serum samples from 88 primary CRC patients and 11 healthy controls were performed. The expression levels of miRNAs in the culture medium of five colon cancer cell lines were also compared with those in the culture medium of a normal colon-derived cell line. The expression profiles of miRNAs that were differentially expressed between CRC and control sample sets were verified using 29 paired samples from post-tumor resection patients. The sensitivities of selected miRNAs as biomarkers of CRC were evaluated and compared with those of known tumor markers (CA19-9 and CEA) using a receiver operating characteristic analysis. The expression levels of selected miRNAs were also validated by quantitative real-time RT-PCR analyses of an independent set of 13 CRC patients. Results The serum exosomal levels of seven miRNAs (let-7a, miR-1229, miR-1246, miR-150, miR-21, miR-223, and miR-23a) were significantly higher in primary CRC patients, even those with early stage disease, than in healthy controls, and were significantly down-regulated after surgical resection of tumors. These miRNAs were also secreted at significantly higher levels by colon cancer cell lines than by a normal colon-derived cell line. The high sensitivities of the seven selected exosomal miRNAs were confirmed by a receiver operating characteristic analysis. Conclusion Exosomal miRNA signatures appear to mirror pathological changes of CRC patients and several miRNAs are promising biomarkers for non-invasive diagnosis of the disease.

[1]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[2]  H. Nakagama,et al.  Functional screening using a microRNA virus library and microarrays: a new high-throughput assay to identify tumor-suppressive microRNAs. , 2010, Carcinogenesis.

[3]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[4]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[5]  Vishnu Swarup,et al.  Circulating (cell‐free) nucleic acids – A promising, non‐invasive tool for early detection of several human diseases , 2007, FEBS letters.

[6]  K. Drescher,et al.  Exosomal miRNAs: Biological Properties and Therapeutic Potential , 2012, Front. Gene..

[7]  T. Jiang,et al.  MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2 , 2012, Journal of Cancer Research and Clinical Oncology.

[8]  M. Brattain,et al.  Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. , 1988, Cancer research.

[9]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[10]  Axel Benner,et al.  Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer , 2012, Clinical Cancer Research.

[11]  D. Ichikawa,et al.  Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer , 2013, British Journal of Cancer.

[12]  Y. Toiyama,et al.  Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. , 2013, Journal of the National Cancer Institute.

[13]  R. Xing,et al.  MiR‐23a in amplified 19p13.13 loci targets metallothionein 2A and promotes growth in gastric cancer cells , 2013, Journal of cellular biochemistry.

[14]  G. Kristiansen,et al.  Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? , 2014, World Journal of Urology.

[15]  T. Chen,et al.  WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. , 1987, Cancer genetics and cytogenetics.

[16]  Y. Akimoto,et al.  Exosome-like vesicles with dipeptidyl peptidase IV in human saliva. , 2008, Biological & pharmaceutical bulletin.

[17]  R. Biondi,et al.  Differential Stability of Cell-Free Circulating microRNAs: Implications for Their Utilization as Biomarkers , 2013, PloS one.

[18]  Cicek Gercel-Taylor,et al.  MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. , 2008, Gynecologic oncology.

[19]  Yingjian Chen,et al.  Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[20]  Zhaohui Huang,et al.  Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer , 2010, International journal of cancer.

[21]  H. Aburatani,et al.  Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. , 2011, Cancer research.

[22]  Robert L Moritz,et al.  Exosomes: proteomic insights and diagnostic potential , 2009, Expert review of proteomics.

[23]  Cancer,et al.  Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial , 2010, The Lancet.

[24]  M. Nykter,et al.  Circulating Plasma MiR-141 Is a Novel Biomarker for Metastatic Colon Cancer and Predicts Poor Prognosis , 2011, PloS one.

[25]  A. Leibovitz,et al.  Classification of human colorectal adenocarcinoma cell lines. , 1976, Cancer research.

[26]  M. Bretthauer.  Evidence for colorectal cancer screening. , 2010, Best practice & research. Clinical gastroenterology.

[27]  R. Aharonov,et al.  MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.

[28]  Hamid Cheshmi.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers , 2011 .

[29]  E. Ng,et al.  Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening , 2009, Gut.

[30]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[31]  D. Chopra,et al.  Primary and long term epithelial cell cultures from human fetal normal colonic mucosa , 1984, In Vitro.

[32]  Tongyu Lin,et al.  Circulating miR‐221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression , 2010, Journal of gastroenterology and hepatology.

[33]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[34]  C. Croce,et al.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review , 2012, EMBO molecular medicine.

[35]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  H. Matsubara,et al.  Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma , 2013, British Journal of Cancer.

[37]  H. Brenner,et al.  MicroRNA Signatures: Novel Biomarker for Colorectal Cancer? , 2011, Cancer Epidemiology, Biomarkers & Prevention.